Brief: Verona Pharma Says US FDA Has Accepted New Drug Application Filing For Ensifentrine For Maintenance Treatment Of COPD
11/09/2023 07:01
Sept 11 (Reuters) - Verona Pharma PLC I9SAy.F :
* VERONA PHARMA ANNOUNCES THE US FDA HAS ACCEPTED THE NEW
DRUG
APPLICATION FILING FOR ENSIFENTRINE FOR THE MAINTENANCE
TREATMENT OF COPD
* VERONA PHARMA PLC SAYS PDUFA TARGET ACTION DATE OF JUNE
26, 2024
Source text for Eikon: ID:nGNXbCSXkg
Further company coverage: I9SAy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak